415 Capital
415 Capital is a Munich-based specialist venture capital firm founded in 2018 that invests in early- and development-stage medical technology companies across Europe, Israel, and the United States. It is led by Managing Directors Frank Groenewegen and Frederik Groenewegen.
- Company typePrivate
- Founded2018
- HeadquartersMunich, Germany
- Headcount1–10
- GTM typeB2B
- OfferingServices
What 415 Capital does
415 Capital is a specialist venture capital firm founded in 2018 and headquartered in Munich, Germany. The firm focuses exclusively on early- and development-stage medical technology companies, with a stated geographic mandate spanning Europe, Israel, and the United States. The firm operates with a small team of 1-10 employees and is led by Managing Directors Frank Groenewegen and Frederik Groenewegen.
The firm's business model is that of a traditional specialist venture capital investor: it deploys capital from one or more funds into medtech portfolio companies and generates returns through equity realization events such as IPOs, M&A, or secondary sales, supplemented by annual management fees charged to limited partners. Confirmed investment activity includes participation in Endovascular Engineering's (E2) $42 million Series B financing and a subsequent $80 million oversubscribed Series C round announced in April 2026, alongside a consortium of institutional healthcare investors including Gilde Healthcare, Norwest, Santé Ventures, S3 Ventures, Panakès Partners, and M&L Healthcare Investments. E2, based in Menlo Park, is commercializing the Helo thrombectomy platform for pulmonary embolism treatment, indicating 415 Capital's willingness to back commercial-stage medtech assets.
The source material does not disclose 415 Capital's fund size, AUM, total portfolio count, LP base, management fee structure, or investment track record beyond the E2 relationship. The firm's own website returned a verification page during data collection, limiting first-party disclosure. As a result, key dimensions of the business — fund vintage, deployment pace, realized returns, and capital availability for new investments — remain opaque from public sources.
415 Capital firmographics
Firmographics- Name
- 415 Capital
- Website
- https://415capital.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- 415 Capital is a Munich-based specialist venture capital firm founded in 2018 that invests in early- and development-stage medical technology companies across Europe, Israel, and the United States. It is led by Managing Directors Frank Groenewegen and Frederik Groenewegen.
- Ownership category
- akta.pro rank
415 Capital industry classification
Industry- Product category
- Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where 415 Capital is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Markets served
415 Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
415 Capital product offering
Product offeringCore offering
415 Capital is a specialist venture capital firm that invests in early- and development-stage medical technology companies headquartered in Europe, Israel, and the United States. The firm provides venture funding and strategic support to portfolio companies developing innovative medical devices and healthcare technologies, including notable investments in commercial-stage companies such as Endovascular Engineering.
Differentiator
Problem solved
Functional benefit
Products and services
- Venture Capital Investments in Medical Technology Companies Early- and development-stage venture capital funding for medical technology companies headquartered in Europe, Israel, and the United States. The service targets medtech startups developing innovative medical devices and healthcare technologies and includes participation in successive funding rounds.
415 Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
415 Capital partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights4 records
415 Capital competitors and assessment
Company assessmentRegional players
- Earlybird Venture Capital: Berlin/Munich-based pan-European early-stage VC with a healthcare and medtech practice; comparable geographic positioning and stage focus, though broader across tech verticals.
- Wellington Partners: Munich-based venture capital firm investing across life sciences, tech, and digital health. Comparable as a Munich-based European healthcare investor; broader than 415 Capital's medtech-only focus.
Direct peers
- LSP (Life Sciences Partners): Amsterdam-based specialist healthcare and life sciences investor with European footprint. Highly comparable as a sector-specialist medtech and life sciences VC.
- M&L Healthcare Investments: Sector-focused healthcare investor that participated alongside 415 Capital in E2's Series C. Directly comparable as a specialist medtech co-investor in development-stage rounds.
- TVM Capital Healthcare: Specialist international healthcare and medtech VC with European and US presence; comparable as a sector-focused, transatlantic medtech investor at similar stages.
- Gilde Healthcare: Dutch-based specialist healthcare and medtech investor; co-led E2's Series C alongside Norwest with 415 Capital participating. Closest comparable in stage, sector focus, and European origin.
- Santé Ventures: US-based early-stage healthcare and medtech specialist VC; participated alongside 415 Capital in E2's Series C. Directly comparable as a sector-focused, development-stage medtech investor.
- S3 Ventures: Texas-based early-stage tech and healthcare investor; participated in E2's Series C with 415 Capital. Comparable as a development-stage healthcare investor with US deal flow.
- Panakès Partners: Milan-based venture capital investor focused on medical technologies, digital health, and life sciences; co-invested with 415 Capital in E2's Series C. Directly comparable as a European medtech specialist.
Broad incumbents
- Norwest Venture Partners: Large US venture firm with a dedicated healthcare practice; co-led E2's Series C. Operates broadly across sectors but is comparable in its medtech investment activity and syndicate leadership.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
415 Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
415 Capital leadership team
Management profileNumber of profiles
Profiles2 records
415 Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
415 Capital M&A and investment
M&A and investmentM&A
Investments17 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 415 Capital
What does 415 Capital do?
415 Capital is a specialist venture capital firm that invests in early- and development-stage medical technology companies headquartered in Europe, Israel, and the United States. The firm provides venture funding and strategic support to portfolio companies developing innovative medical devices and healthcare technologies, including notable investments in commercial-stage companies such as Endovascular Engineering.
Is 415 Capital a public or private company?
415 Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was 415 Capital founded?
415 Capital was founded in 2018. It employs 1 to 10 people.
Where is 415 Capital based?
415 Capital is headquartered in Munich, Germany, in the Europe region.
Who are 415 Capital's main competitors?
Regional players on record are Earlybird Venture Capital and Wellington Partners. Direct peers are LSP (Life Sciences Partners), M&L Healthcare Investments, TVM Capital Healthcare, Gilde Healthcare, Santé Ventures, S3 Ventures and Panakès Partners. Norwest Venture Partners is listed as a broad incumbent.
Does 415 Capital have an API?
No public API is recorded for 415 Capital.
What industry is 415 Capital in?
415 Capital's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.